Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia

Maturitas. 2020 Jul:137:57-62. doi: 10.1016/j.maturitas.2020.04.019. Epub 2020 May 6.

Abstract

COVID-19 is associated with a systemic inflammatory response with activation of coagulation in symptomatic patients. The possibility of coagulopathies in peri- and postmenopausal women taking estrogen therapies makes it necessary to consider antithrombotic strategies, such as the use of low molecular weight heparins (LMWH) at specific prophylactic or treatment doses for each individual case, depending on the risk factors that each woman presents. For such reasons, a panel of experts from various Spanish scientific societies has met to develop usage recommendations for managing menopausal women taking menopausal hormone therapy (MHT) or combined hormonal contraception (CHC) during the COVID-19 pandemic.

Keywords: COVID-19; Hormone menopause therapy; Venous thromboembolism prophylaxis.

Publication types

  • Practice Guideline

MeSH terms

  • Anticoagulants / therapeutic use
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections* / complications
  • Coronavirus Infections* / epidemiology
  • Estrogen Replacement Therapy*
  • Female
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Hormonal Contraception
  • Hormone Replacement Therapy*
  • Humans
  • Menopause*
  • Middle Aged
  • Pandemics*
  • Pneumonia, Viral* / complications
  • Pneumonia, Viral* / epidemiology
  • Risk Factors
  • SARS-CoV-2
  • Thromboembolism* / etiology
  • Thromboembolism* / prevention & control

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight